Floatz logo

Romidepsin

Atypical Teratoid/Rhabdoid Tumor (AT/RT)

Masonic Cancer Center, University of MinnesotaSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Atypical Teratoid/Rhabdoid Tumor (AT/RT) cohort.

Asset / SponsorPhaseRating
Carboplatin
Masonic Cancer Center, University of Minnesota
N/AD
Lorazepam
Masonic Cancer Center, University of Minnesota
N/AD
Busulphan
Masonic Cancer Center, University of Minnesota
N/AD
Fludarabine
Masonic Cancer Center, University of Minnesota
N/AD
Keppra
Masonic Cancer Center, University of Minnesota
N/AD

View all 10 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →